Scancell (LON:SCLP) Hits New 12-Month Low – Time to Sell?

Scancell Holdings plc (LON:SCLP)’s share price reached a new 52-week low on Wednesday. The company traded as low as GBX 85.20 and last traded at GBX 85.20, with a volume of 321,031 shares traded. The stock had previously closed at GBX 86.40.

Scancell Price Performance

The company has a market capitalization of £1.13 billion, a P/E ratio of -151.82 and a beta of 0.69. The stock’s fifty day simple moving average is GBX 94.23 and its 200-day simple moving average is GBX 132.25. The company has a debt-to-equity ratio of -88.01, a current ratio of 0.28 and a quick ratio of 13.01.

Scancell (LON:SCLP) last posted its quarterly earnings data on Friday, October 9th. The company reported GBX (17.30) EPS for the quarter. Scancell had a positive return on equity of 128.87% and a negative net margin of 116.98%. On average, equities analysts forecast that Scancell Holdings plc will post -2.54 earnings per share for the current fiscal year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.